Chemoembolization, Therapeutic: Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.Ethiodized Oil: Ethyl ester of iodinated fatty acid of poppyseed oil. It contains 37% organically bound iodine and has been used as a diagnostic aid (radiopaque medium) and as an antineoplastic agent when part of the iodine is 131-I. (From Merck Index, 11th ed)Iodized Oil: A preparation of oil that contains covalently bound IODINE. It is commonly used as a RADIOCONTRAST AGENT and as a suspension medium for CHEMOTHERAPEUTIC AGENTS.Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.Liver Neoplasms: Tumors or cancer of the LIVER.Gelatin Sponge, Absorbable: Sterile, gelatin-base surgical sponge applied topically as an adjunct to hemostasis when the control of bleeding by conventional procedures is ineffective to reduce capillary ooze or is impractical. (From AMA Drug Evaluations Annual, 1994, p797)Hepatic Artery: A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum.Polyvinyl Alcohol: A polymer prepared from polyvinyl acetates by replacement of the acetate groups with hydroxyl groups. It is used as a pharmaceutic aid and ophthalmic lubricant as well as in the manufacture of surface coatings artificial sponges, cosmetics, and other products.Infusions, Intra-Arterial: Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.Magnetic Resonance Imaging, Interventional: Minimally invasive procedures guided with the aid of magnetic resonance imaging to visualize tissue structures.Embolization, Therapeutic: A method of hemostasis utilizing various agents such as Gelfoam, silastic, metal, glass, or plastic pellets, autologous clot, fat, and muscle as emboli. It has been used in the treatment of spinal cord and INTRACRANIAL ARTERIOVENOUS MALFORMATIONS, renal arteriovenous fistulas, gastrointestinal bleeding, epistaxis, hypersplenism, certain highly vascular tumors, traumatic rupture of blood vessels, and control of operative hemorrhage.Microspheres: Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Hepatectomy: Excision of all or part of the liver. (Dorland, 28th ed)Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.alpha-Fetoproteins: The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.Catheter Ablation: Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias.Portal Vein: A short thick vein formed by union of the superior mesenteric vein and the splenic vein.Yttrium Radioisotopes: Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.Standard of Care: The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Maxillary Artery: A branch of the external carotid artery which distributes to the deep structures of the face (internal maxillary) and to the side of the face and nose (external maxillary).Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Surgical Sponges: Gauze material used to absorb body fluids during surgery. Referred to as GOSSYPIBOMA if accidentally retained in the body following surgery.Antibiotics, Antineoplastic: Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.Hemostatics: Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.Catheterization, Peripheral: Insertion of a catheter into a peripheral artery, vein, or airway for diagnostic or therapeutic purposes.Liver Transplantation: The transference of a part of or an entire liver from one human or animal to another.Niacinamide: An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.Phenylurea Compounds: Compounds that include the amino-N-phenylamide structure.Preoperative Care: Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed)Contrast Media: Substances used to allow enhanced visualization of tissues.Angiography, Digital Subtraction: A method of delineating blood vessels by subtracting a tissue background image from an image of tissue plus intravascular contrast material that attenuates the X-ray photons. The background image is determined from a digitized image taken a few moments before injection of the contrast material. The resulting angiogram is a high-contrast image of the vessel. This subtraction technique allows extraction of a high-intensity signal from the superimposed background information. The image is thus the result of the differential absorption of X-rays by different tissues.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Benzenesulfonates: Organic salts and esters of benzenesulfonic acid.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.CyclobutanesNecrosis: The pathological process occurring in cells that are dying from irreparable injuries. It is caused by the progressive, uncontrolled action of degradative ENZYMES, leading to MITOCHONDRIAL SWELLING, nuclear flocculation, and cell lysis. It is distinct it from APOPTOSIS, which is a normal, regulated cellular process.Injections, Intra-Arterial: Delivery of drugs into an artery.Antineoplastic Protocols: Clinical protocols used to inhibit the growth or spread of NEOPLASMS.Catheterization: Use or insertion of a tubular device into a duct, blood vessel, hollow organ, or body cavity for injecting or withdrawing fluids for diagnostic or therapeutic purposes. It differs from INTUBATION in that the tube here is used to restore or maintain patency in obstructions.Gastric Fistula: Abnormal passage communicating with the STOMACH.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.Liver Circulation: The circulation of BLOOD through the LIVER.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.Portography: Examination of the portal circulation by the use of X-ray films after injection of radiopaque material.Angiography: Radiography of blood vessels after injection of a contrast medium.Waiting Lists: Prospective patient listings for appointments or treatments.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.Liver Neoplasms, Experimental: Experimentally induced tumors of the LIVER.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Bile Ducts, Intrahepatic: Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.Palliative Care: Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)Radiotherapy, Conformal: Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.Starch: Any of a group of polysaccharides of the general formula (C6-H10-O5)n, composed of a long-chain polymer of glucose in the form of amylose and amylopectin. It is the chief storage form of energy reserve (carbohydrates) in plants.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.

Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. (1/507)

Thirty-seven cirrhotic patients with 62 hepatocellular carcinoma (HCC) foci--most Child-Pugh class B or C and/or with large, inoperable tumours--underwent 148 sessions of transcatheter arterial chemoembolization (TACE) using lipiodol, doxorubicin and cisplatin. Treatment efficacy was assessed by serial hepatic arteriography in 34/37 (91.9%) patients and abdominal CT scanning in 3/37 (8.1%) patients. Child-Pugh status was determined prior to each treatment session. Varying degrees of control of tumour neovascularity occurred for a median 390 days (range 90 to > 1680 days) in 33/34 (97.1%) patients in whom progress hepatic arteriography was performed. Ablation of tumour neovascularity occurred in 6/6 (100%), 4/12 (33.3%) and 6/16 (37.5%) patients with HCC diameters < 4 cm, 4-7 cm and > 8 cm, respectively (p < 0.02). Significantly more sessions were required for ablation of larger tumours (p < 0.05). Recurrent HCC was detected in 50% of patients after a median 240 days (range 60-1120 days). Deterioration in Child-Pugh status followed a session of TACE on 19/148 (12.8%) occasions but resulted in unscheduled hospitalization on only 4/148 (2.7%) occasions, the highest incidence (8.3%) in Child-Pugh C patients. Actuarial survival was 27/36 (75.0%) at 6 months, 17/34 (50.0%) at 12 months, 14/34 (41.2%) at 18 months, 9/31 (29.0%) at 24 months and 4/27 (14.8%) at 36 months. Multi-agent TACE with lipiodol, doxorubicin and cisplatin provides a useful anti-tumour effect, even in cirrhotic patients with large HCCs. The incidence of clinically significant deterioration in hepatic function due to ischaemia of non-tumorous liver is acceptably low, even in Child-Pugh C patients.  (+info)

Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection. (2/507)

A 54-year-old man with medullary thyroid carcinoma in the thyroid gland was unable to undergo total thyroidectomy because the tumor had invaded the mediastinum. Radiation therapy and chemotherapy were given. Seven years later, intractable diarrhea and abdominal pain appeared, and computed tomography demonstrated hypervascular tumors in the thyroid gland and in the liver. The tumors were successfully treated with percutaneous ethanol injection to a lesion in the thyroid gland and transcatheter arterial embolization followed by percutaneous ethanol injection to tumors in the liver. Transcatheter arterial embolization and percutaneous ethanol injection may be valuable in treating medullary thyroid carcinoma.  (+info)

Feasibility and toxicity of chemoembolization for children with liver tumors. (3/507)

PURPOSE: To determine the feasibility, toxicity, and efficacy of hepatic arterial chemoembolization (HACE) in pediatric patients with refractory primary malignancies of the liver. PATIENTS AND METHODS: Six patients with hepatoblastoma (HB), three with hepatocellular carcinoma (HCC), and two with undifferentiated sarcoma of the liver were treated with HACE every 2 to 4 weeks until their tumors became surgically resectable or they showed signs of disease progression. All but one newly diagnosed patient with HCC had previously received systemic chemotherapy. RESULTS: All patients with HB and HCC responded to HACE, as measured by imaging studies and alpha-fetoprotein levels. Surgical resection (complete or microscopic residual disease) was feasible in five of 11 patients, and three patients remain alive with no evidence of disease. Elevated liver transaminase and bilirubin levels were seen after each one of the 46 courses of HACE. Other toxicities included fever, pain, nausea, vomiting, and transient coagulopathy. CONCLUSION: HACE is feasible, well tolerated, and effective in inducing surgical resectability of primary hepatic tumors in children.  (+info)

Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. (4/507)

OBJECTIVE: To assess the influence of preoperative portal vein embolization (PVE) on the long-term outcome of liver resection for colorectal metastases. SUMMARY BACKGROUND DATA: Preoperative PVE of the liver induces hypertrophy of the remnant liver and increases the safety of hepatectomy. METHODS: Thirty patients underwent preoperative PVE and 88 patients did not before resection of four or more liver segments. PVE was performed when the estimated rate of remnant functional liver parenchyma (ERRFLP) assessed by CT scan volumetry was less than 40%. RESULTS: PVE was feasible in all patients. There were no deaths. The complication rate was 3%. The post-PVE ERRFLP was significantly increased compared with the pre-PVE value. Liver resection was performed after PVE in 19 patients (63%), with surgical death and complication rates of 4% and 7% respectively. PVE increased the number of resections of more than four segments by 19% (17/88). Actuarial survival rates after hepatectomy with or without previous PVE were comparable: 81%, 67%, and 40% versus 88%, 61%, and 38% at 1, 3, and 5 years respectively. CONCLUSIONS: PVE allows more patients with previously unresectable liver tumors to benefit from resection. Long-term survival is comparable to that after resection without PVE.  (+info)

Malignant insulinoma which expressed a unique creatine kinase isoenzyme: clinical value of arterial embolization as a palliative therapy. (5/507)

A 76-year-old man with hypoglycemic coma was diagnosed as malignant insulinoma with multiple hepatic metastases. Embolization was done for two-thirds of the hepatic mass and it rapidly lowered the serum immunoreactive insulin. He was discharged without medication and has been free from hypoglycemia. After the embolization, the serum creatine kinase (CK) level increased transiently although there was no evidence of myocardial infarction. On electrophoresis, the CK activity showed an abnormal peak, suggesting mitochondrial CK. CK release after embolization has been reported in only a few cases with endocrine tumors, which might indicate some relationship between active energy metabolism and mitochondrial CK.  (+info)

Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. (6/507)

OBJECTIVE: To evaluate the current knowledge on the risk factors for recurrence, efficacy of adjuvant therapy in preventing recurrence, and the optimal management of recurrence after resection of hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: The long-term prognosis after resection of HCC remains unsatisfactory as a result of a high incidence of recurrence. Prevention and effective management of recurrence are the most important strategies to improve the long-term survival results. METHODS: A review of relevant English articles was undertaken based on a Medline search from January 1980 to July 1999. RESULTS: Pathologic factors indicative of tumor invasiveness such as venous invasion, presence of satellite nodules, large tumor size, and advanced pTNM stage, are the best-established risk factors for recurrence. Active hepatitis activity in the nontumorous liver and perioperative transfusion also appear to enhance recurrence. Recent molecular research has identified tumor biologic factors such as the proliferative and angiogenic activities of the tumor as new risk factors for recurrence. There is a lack of convincing evidence for the efficacy of neoadjuvant or adjuvant therapy in preventing recurrence. Retrospective studies suggested that postoperative hepatic arterial chemotherapy might improve disease-free survival, but results were conflicting. For the management of postoperative recurrence, studies have consistently indicated that surgical resection should be the treatment of choice for localized recurrence, be it in the liver remnant or extrahepatic organs. Transarterial chemoembolization and percutaneous ethanol injection are widely used to prolong survival in patients with unresectable intrahepatic recurrence, and combined therapy with these two modalities may offer additional benefit. CONCLUSIONS: Knowledge of the risk factors for postoperative recurrence provides a basis for logical approaches to prevention. Minimal surgical manipulation of tumors to prevent tumor cell dissemination, avoidance of perioperative blood transfusion, and suppression of chronic hepatitis activity in the liver remnant are strategies that may be useful in preventing recurrence. The efficacy of postoperative adjuvant regional chemotherapy deserves further evaluation. New concepts on the influence of tumor biologic factors such as angiogenic activity on recurrence of HCC suggest a potential role of novel approaches such as antiangiogenesis for adjuvant therapy in the future. Currently, the most realistic approach in prolonging survival after resection of HCC is early detection and aggressive management of recurrence. Randomized trials are needed to define the roles of various treatment modalities for recurrence and the benefit of multimodality therapy.  (+info)

Uterine fibroid embolization. (7/507)

Interventional radiologists have performed uterine artery embolization to treat women with emergency uterine bleeding since the 1970s. In this procedure, the physician guides a small angiographic catheter into the uterine arteries and injects a stream of tiny particles that decreases blood flow to the uterus. It is now considered a safe and highly effective nonsurgical treatment of women with symptomatic uterine fibroid tumors. Uterine fibroid embolization has several advantages over conventional hormonal suppression and surgical procedures, including avoidance of the side effects of drug therapy and the physical and psychologic trauma of surgery. In addition, after uterine fibroid embolization, patients can normally resume their usual activities several weeks earlier than they can after hysterectomy. Along with hysteroscopic resection, myolysis and laparoscopic myomectomy, uterine fibroid embolization widens treatment options for patients who desire to avoid hysterectomy.  (+info)

Nonsurgical treatment of hepatocellular carcinoma. (8/507)

1. Outcome from nonsurgical treatment is directly related to stage of hepatocellular cancer (HCC) and degree of liver function impairment. 2. Ablative percutaneous procedures, such as alcohol injection or radiofrequency thermal therapy, are most effective in the destruction of solitary tumors of 3 cm or less. 3. In most cases, nonsurgical treatments are not curative, but may slow tumor progression and can provide palliation. 4. Arterial embolization or chemoembolization has an antitumor effect, but it has not been shown to affect patient outcome. 5. Radiation therapy, chemotherapy, hormonal manipulation, and interferon have not been consistently effective in HCC. 6. Ablative procedures, embolization, and systemic chemotherapy should be avoided in patients with advanced cirrhosis.  (+info)

*List of MeSH codes (E02)

... chemoembolization, therapeutic MeSH E02.565.280.853 --- short-wave therapy MeSH E02.565.280.945 --- ultrasonic therapy MeSH ... therapeutic touch MeSH E02.190.901.968 --- witchcraft MeSH E02.190.901.984 --- yoga MeSH E02.218.085.090 --- body piercing MeSH ... therapeutic touch MeSH E02.190.525.937 --- yoga MeSH E02.190.599.186 --- kinesiology, applied MeSH E02.190.599.233 --- ...

*Achim Peters

... chemoembolization as a therapeutic option]. Med Klin 96:632-636 Deininger E, Oltmanns KM, Wellhoener P, Fruehwald-Schultes B, ...

*Therapeutic index

... as is done in peptide receptor radionuclide therapy for neuroendocrine tumors and in chemoembolization or radioactive ... The therapeutic index (TI) (also referred to as therapeutic ratio) is a comparison of the amount of a therapeutic agent that ... a drug or other therapeutic agent with a narrow therapeutic range (i.e. having little difference between toxic and therapeutic ... The effective therapeutic index can be affected by targeting, in which the therapeutic agent is concentrated in its area of ...

*Hepatic artery embolization

Hepatic artery chemoembolization (HACE), sometimes called transarterial chemoembolization (TACE), combines hepatic artery ... Hepatic artery embolization (HAE), also known as trans-arterial embolization (TAE), is one of the several therapeutic methods ... Arterial Chemotherapy Infusion of the Liver (and) Chemoembolization of the Liver (TACE)[3]). Leal, Julie N; Kingham, T. Peter ( ... The role of surgery and chemoembolization in the management of carcinoid. California Carcinoid Fighters Conference. October 25 ...

*Neuroendocrine tumor

Hepatic artery chemoembolization (HACE), sometimes called transarterial chemoembolization (TACE), combines hepatic artery ... Carcinoid Tumors and the Carcinoid Syndrome: What's New in the Therapeutic Pipeline. (The Carcinoid Cancer Foundation: ... Arterial Chemotherapy Infusion of the Liver (and) Chemoembolization of the Liver (TACE) medicinenet.com; accessed November 8, ... The role of surgery and chemoembolization in the management of carcinoid. California Carcinoid Fighters Conference. October 25 ...

*Selective internal radiation therapy

Currently, therapeutic doses of radiation can be targeted to tumors with great accuracy using linear accelerators (see ... A recent single-blinded, prospective randomized trial was the first to compare transarterial chemoembolization (TACE) and Y-90 ... Targeted alpha-particle therapy Transcatheter arterial chemoembolization Atassi, B; Gates VL; Lewandowski RJ; et al. (2007). " ... The chemotherapeutic analogue (combining chemotherapy with embolization) is called chemoembolization, of which transcatheter ...

*Embolization

When it bears a chemotherapy drug, the process is called chemoembolization. Transcatheter arterial chemoembolization (TACE) is ... It may be pathological (in which sense it is also called embolism), for example a pulmonary embolism, or therapeutic, as a ... Treated either by particle infarction or transcatheter arterial chemoembolization (TACE). Uterine fibroids Arteriovenous ...

*Lipiodol

Recently there has been an increasing interest in the use of Lipiodol as a therapeutic agent in the management of unexplained ... It is used in chemoembolization applications as a contrast agent in follow-up imaging. Lipiodol is also used in ... computed tomography in the management of hepatocellular carcinoma with transcatheter arterial chemoembolization". J ...

*Ultrasonography of liver tumors

Transarterial chemoembolization (TACE) is part of palliative therapies for HCC used in intermediate stages of the disease. It ... Monitoring TACE therapeutic results by contrast imaging techniques is performed as for ablative therapies initially after one ... On the other hand, CE-CT is also limited by the presence of Lipiodol (iodine oil), therefore the evaluation of therapeutic ... CEUS also allows assessment of therapeutic effect immediately post-procedure (with the possibility of reintervention in case of ...

*Interventional oncology

Transarterial chemoembolization (TACE): delivery of intra-arterial chemotherapy to the liver through a catheter in combination ... 1930 - First therapeutic embolization procedure (of a carotid-cavernous fistula); described by Brooks. 1960s - Radioisotopes ... Drug eluting bead chemoembolization (DEB-TACE): delivery of microparticles that are themselves loaded with the chemotherapy ... Therapeutic interventional oncology procedures may be classified further into ablation techniques that destroy neoplastic ...

*Liver support systems

... are therapeutic devices to assist in performing the functions of the liver in persons with liver damage. ... Liver Resection in hepatocellular carcinoma Transarterial Chemoembolization (TACE) Partial resection in living donor ... Pathophysiological basis of therapeutic options". Blood Purif. 20 (3): 252-261. doi:10.1159/000047017. PMID 11867872. Stravitz ... Therapeutic Apheresis and Dialysis. 13 (6): 549-55. doi:10.1111/j.1744-9987.2009.00708.x. PMID 19954480. Steiner, C; Mitzner, S ...

*Tegafur/uracil

Nakayama T, Noguchi S (2010). "Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in ... "Adjuvant chemotherapy with tegafur/uracil administration after transcatheter arterial chemoembolization for advanced ...

*Interventional radiology

Ablative Chemoembolization: combined injection of chemotherapy and embolic agents into the arterial blood supply of a tumor, ... Interventional radiologists commonly perform both diagnostic and therapeutic procedures, although diagnostic angiography is ...
Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Chronic hepatitis B infection is the common etiology for the development of HCC. Transcatheter arterial chemoembolization (TACE) is the traditional method for the palliative management of patients with HCC. Few previous studies had demonstrated that the serum level of anticancer drug from patients treated by TACE was similar to those treated by systemic chemotherapy. Since systemic chemotherapy may have the possibility to influence patients general defense ability, hepatitis B virus may reactivate after chemotherapy. There is no study to investigate the possibility of TACE in the reactivation of hepatitis B virus. This project will collect 20 patients with HCC caused by hepatitis B who are planned to be treated by TACE. Quantitative determination of viral load in blood will be performed before TACE, the first and the third month after TACE to investigate the influence of TACE on hepatitis B virus replication. This ...
TY - JOUR. T1 - Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine-Enhanced Liver Magnetic Resonance. AU - Chu, Linda Chi Hang. AU - Pozzessere, Chiara. AU - Corona Villalobos, Celia. AU - Castaños, Sandra. AU - Rastegar, Neda. AU - Halappa, Vivek. AU - Bonekamp, Susanne. AU - Emurano, Emi. AU - Kamel, Ihab R. PY - 2016/9/27. Y1 - 2016/9/27. N2 - OBJECTIVE: Use of gadobenate dimeglumine-enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine-enhanced MR examination at baseline and 1-month follow-up after TACE. Nodule size, enhancement, and apparent diffusion coefficient were measured for both examinations by 2 reviewers. Changes in tumor nodule size, enhancement, and apparent diffusion coefficient were evaluated ...
Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumors blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways. The radiotherapeutic analogue (combining radiotherapy with embolization) is called radioembolization or selective internal radiation therapy (SIRT). TACE derives its beneficial effect by two primary mechanisms. Most tumors within the liver are supplied by the proper hepatic artery, so arterial embolization preferentially interrupts the tumors blood supply and stalls growth until neovascularization. Secondly, focused administration of chemotherapy allows for delivery of a higher dose to the tissue while simultaneously reducing systemic exposure, ...
2016 SIR Purpose To measure transarterial chemoembolization utilization and survival benefit among patients with hepatocellular carcinoma (HCC) in the Surveillance, Epidemiology, and End Results (SEER) patient population. Materials and Methods A retrospective study identified 37,832 patients with HCC diagnosed between 1991 and 2011. Survival was estimated by Kaplan-Meier method and compared by log-rank test. Propensity-score matching was used to address an imbalance of covariates. Results More than 75% of patients with HCC did not receive any HCC-directed treatment. Transarterial chemoembolization was the most common initial therapy (15.9%). Factors associated with the use of chemoembolization included younger age, more HCC risk factors, more comorbidities, higher socioeconomic status, intrahepatic tumor, unifocal tumor, vascular invasion, and smaller tumor size (all P < .001). Median survival was improved in patients treated with chemoembolization compared with those not treated with ...
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking blood flow to the tumor. Giving sorafenib tosylate before and after chemoembolization may kill more tumor cells.. PURPOSE: This phase II trial is studying the side effects and how well giving sorafenib tosylate before and after hepatic arterial chemoembolization with doxorubicin hydrochloride and mitomycin C works in treating patients with localized liver cancer that cannot be removed by surgery. ...
In the current issue, Kim et al. conducted a retrospective study comparing scheduled repetition of chemoembolization with on demand approach [6]. In multivariate analysis, scheduled repetition of chemoembolization was an independent favorable prognostic factor for survival. However, in the manuscript, there were no supporting data how scheduled repetition of chemoembolization led to survival improvement. How many patients had residual viable tumor on scheduled 2nd chemoembolization? Was scheduled 2nd chemoembolization significantly decreased the rate of locally invasive recurrence or chemoembolization failure? Was scheduled 2nd chemoembolization decreased remote intrahepatic recurrence or distant metastasis rate? They reported that treatment strategy (scheduled vs. on-demand) was not associated with recurrence-free survival (39.7% vs. 49.2% at 1 year, P=0.26) and local recurrence-free survival (68.3% vs. 66.8% at 1 year, P=0.38). Retrospective series are prone to selection bias. I believe there ...
Both transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection therapy (PEI) have proven their efficacy in patients with unresectable hepatocellular carcinoma (HCC): TACE mainly in large lesions or disseminated disease and PEI in solitary lesions smaller than 3 cm. Although
Background and Aim: This study aimed to evaluate the therapeutic efficacy and safety of repeated transarterial chemoembolization (TACE) with additional radiation therapy (RT) in hepatocellular carcinoma (HCC) with portal vein (PV) invasion.. Methods: We performed survival analysis of consecutive HCC patients with PV invasion according to the treatment modalities after stratification by the degree of PV invasion and liver function retrospectively.. Results: During 2005, 281 patients were newly diagnosed to have HCC with PV invasion at our institution. Repeated TACE or transarterial chemoinfusion (TACI) was performed in 202 (71.9%) patients and additional RT was performed for PV invasion in 43 of them. A total of 281 patients had a median survival of 5.2 months and a 2-year survival rate (YSR) of 19.2%. Repeated TACE showed significant survival benefits compared with conservative management in patients with PV branch invasion; median survival and 2-YSR was 10.2 vs 2.3 months and 33.7% vs 0% in ...
There was no difference in clinical background between these groups. Complete response to therapy was noted in 29 (96.3%) patients of the SBRT group, and in only one (3.3%) patient of the TACE group (P , 0.001). None of the patients developed acute hematologic toxicity of more than Common Terminology Criteria for Adverse Events Grade 3 during and after the treatment. Furthermore, none of the SBRT group developed radiation-induced liver damage. Disease-free survival of the 12 patients without previous HCC treatments in SBRT group was significantly superior to that in control group (15.7 months vs 4.2 months; P = 0.029). ...
AbstractWe aim to investigate the effects of postoperative adjuvant transarterial chemoembolization (TACE) on survival and recurrence in hepatocellular carcinoma (HCC) patients after radical resection. A total of 320 HCC patients underwent radical resection between January 2010 and January 2014 in Q
Transarterial chemoembolization may be offered as a main treatment for liver cancer or for people waiting for a transplant. Learn about TACE for liver cancer.
Full Title MCT: A Multicenter Pilot Study of Nivolumab with Drug Eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma Purpose Liver cancers that cannot be surgically removed or treated with liver transplantation are sometimes treated with embolization. Chemoembolization is when doctors perform a procedure to send tiny glass beads with chemotherapy through the arteries supplying blood to the tumor, causing the tumor to die. This procedure has been shown to shrink tumors and allow patients with liver cancer to live longer.
The above FLIGHTPLAN FOR LIVER performance aspects reflect the results of four published journal articles1234 that used the FLIGHTPLAN FOR LIVER software or its prototype5.. 1 - Computed Analysis of Three-Dimensional Cone-Beam Computed Tomography Angiography for Determination of Tumor-Feeding Vessels During Chemoembolization of Liver Tumor: A Pilot Study - Deschamps et al. Cardiovasc Intervent Radiol. 2010.. 2 - Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography - Minami et al. Liver Cancer. 2014.. 3 - Clinical utility and limitations of tumor-feeder detection software for liver cancer embolization. Iwazawa et al. European Journal of Radiology. 2013.. 4 - Comparison of the Number of Image Acquisitions and Procedural Time Required for Transarterial Chemoembolization of Hepatocellular Carcinoma with and without Tumor-Feeder Detection Software - Iwazawa et al. Radiology Research and Practice. ...
to hear that the two tace procedures didnt work for you. I can only imagine how you are feeling. My Mom passed away from bile duct cancer and it was a long road so I can understand what you are going through...and want you to know my heart goes out to you and I am praying and pulling for only the best for you and your health. My friend has been very successful with the tace procedure. Im sad to read it didnt help you. Have you thought about getting another opinion? I think that might be a good idea. This is your life, dont ever ever give up! Keep fighting the good fight! What state are you in? I am in Maryland. Hopkins is a great place and can do many wonderful things for people, I hope you will consider another opinion. Please write me if you need a friend at [email protected] I would love to be support for you. Sincerely, Angel. Many hugs! I am pulling for you and praying for the best for you! ...
PurposeThis study was designed to analyze retrospectively the performance of cone-beam computed tomography (CBCT) hepatic arteriography in depicting tumors and their feeders and to investigate the related determining factors in chemoembolization for hepatocellular carcinoma (HCC).MethodsEighty-six patients with 142 tumors satisfying the imaging diagnosis criteria of HCC were included in this study. The performance of CBCT hepatic arteriography for chemoembolization per tumor and per patient was evaluated using maximum intensity projection images alone (MIP analysis) or MIP combined with multiplanar reformation images (MIP + MPR analysis) regarding the following three aspects: tumor depiction, confidence of tumor feeder detection, and trackability of tumor feeders. Tumor size, tumor enhancement, tumor location, number of feeders, diaphragmatic motion, portal vein enhancement, and hepatic artery to parenchyma enhancement ratio were regarded as potential determining factors.ResultsTumors were ...
Embolization was performed, according to the authors, with doxorubicin drug-eluting LC Beads (Biocompatibles) and the particle size was determined by the interventional radiologist performing chemoembolization. Sixty one treated tumours were treated in 61 patients and were assessed for response to the drug-eluting beads. Out of these patients 39 (64%) were treated with 100-300µm particles and 22 patients were treated with 300-500µm.. All chemoembolization procedures were successful and there were no deaths related to the procedure. Patients were followed-up at one month and then every three months as outpatient visits and imaging.. "At baseline patients in the 100-300µm and 300-500µm groups had similar tumour size distributions, said Padia et al. "Although no statistically significant differences in tumour response by either the World Health Organization (WHO) or the European Association for the Study of the Liver (EASL) were seen, there were tendencies toward higher rates of complete ...
In this study, the mean OS for all patients was 80.7 ± 5.6 months, and the 1-, 3-, and 5-year median OS rates were 88.1%, 64.8%, and 49.9%, respectively. Recent studies in which patients with early HCC or HCC , 4 cm received TACE as the initial treatment modality have shown that the 1-, 3-, and 5-year survival rates were 89% to 100%, 63% to 81%, and 43% to 52%, respectively [33-37]. The results of our study are in line with those of these studies. Another study investigated the long-term survival of patients with HCC who met the Milan criteria and underwent RFA (n = 315) or TACE (n = 215) as an initial treatment. The two groups did not show any significant differences in terms of long-term survival rates (the 1-, 3-, and 5-year survival rates were 85%, 60%, and 41% for RFA, and 86%, 55%, and 36% for TACE, respectively) [33]. Recently, Kim et al. [7] reported that TACE can be a viable alternative treatment modality for small HCCs (, 2 cm) when RFA is not indicated, although RFA showed better ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Angiographic imaging allows interventional radiologists during TACE therapy to selectively deliver anti-tumor substances through the arteries.
BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject-specific sections.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
title: Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma, doi: 10.1016/j.jhep.2015.01.022, category: Article
Care guide for Chemoembolization Cancer Therapy (Precare). Includes: possible causes, signs and symptoms, standard treatment options and means of care and support.
Alvaro Paredes , Sergio M. Acuña, Leopoldo Gutiérrez and Pedro G. Toledo Zeta Potential of Pyrite Particles in Concentrated Solutions of Monovalent Seawater Electrolytes and Amyl Xanthate. Minerals 2019, 9(10), 584; doi.org/10.3390/min9100584Full text. Laura M. Henning, Ulla Simon, Aleksander Gurlo, Glen J. Smales and Maged F. Bekheet Grafting and stabilization of ordered mesoporous silica COK-12 with graphene oxide for enhanced removal of methylene blue. doi.org/10.1039/C9RA05541JAbstract. Masakazu Kawashita, Shoji Ueno, Shoma Handa, Maiko Furuya, Kotone Yokota & Hiroyasu Kanetaka In vitro evaluation of doxorubicin-eluting porous titania microspheres for transcatheter arterial chemoembolization. Full text. Tahani Kaldéus, Maria Rosella Telaretti Leggieri, Carmen Cobo Sanchez, Eva Malmström All-Aqueous SI-ARGET ATRP from Cellulose Nanofibrils Using Hydrophilic and Hydrophobic Monomers. Biomacromolecules 2019, 20, 5, 1937-1943 Abstract. Fernando Giacomini, Antônio Augusto Ulson de Souza, ...
The PREMIERE trial prospectively compared chemoembolization and radioembolization in a randomised fashion and this is what physicians have wanted to see for a long time. We started the study in 2009 and had set the sample size at 124 patients. However, what has happened over the last eight years is that radioembolization as a treatment modality has now been adopted routinely and as a result, patients no longer want to be randomised. Out of the 124 patents, we only enrolled 45. We still analysed the data from the 45 patients in a blinded manner. Despite the relatively small sample size, the results were extremely positive. The hazard ratio was 0.13, in other words the risk of progression in the radioembolization arm was 87% less than in the cTACE arm, which is very compelling. Very rarely in cancer studies do you have such low hazard ratios. Despite the small sample size, these statistics are very significant. This is a post hoc analysis but the clinical findings of segmental Y-90 results are ...
Using palliative transarterial chemoembolization (TACE) a reduction of malignant liver neoplasms and a prolongation of survival time can be achieved. During the course of therapy phosphorous magnetic resonance spectroscopy by means of chemical-shift-imaging was used for noninvasive examination of the cellular metabolism of energy and membranes. Differentiation between primary and secondary liver tumors was not feasible using 31P-spectra. After therapy patients had shown increased inorganic phosphate signal and reduction of the ß-NTP-signals, which normalized during six week intervall before next intervention. Response and non-response to therapy showed different courses of spectroscopic quotients during therapy cycle. Prominent reduction of volume as well as homogeneous and continous retention of lipiodol within the tumor are reliable combined with spectroscopic response to therapy. The first group of patients showed these signs at the examination immediately after embolization whereas patients ...
Clinical Cancer Research , 8/2017 Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial. Oncotarget , 2017 Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. OvidInsights , 9/2017 Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort Study of 2 Countries. NEJM , 6/29/2017 Desmoid Tumors and Celecoxib with Sorafenib. KoreaMed Synapse , 3/2017 Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study. Cancer , 8/24/2015 Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. JAMA Dermatol , 9/16/2015 Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade.. Cell , 9/10/2015 Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Ann ...
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the
Vascular Interventional Physicians is an outpatient-style clinic offering convenience and choice to physicians, and to patients who refer themselves.
This study aimed to evaluate the effect of stereotactic ablative radiotherapy (SABR) after incomplete transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients. The study enrolled 178 HCC patients initially treated with TACE between 2006 and 2011. Patients were included if they had Barcelona Clinic Liver Cancer stage 0 or A, ≤3 nodules with a total sum of longest diameter ≤10 cm, Child-Turcotte-Pugh score of ≤7, no major vessel invasion, and no extra-hepatic metastases. Twenty-four patients achieved a complete response to TACE (group 1). Among those with incomplete response, 47 patients received other curative treatments (group 2), 37 received SABR (group 3), and 70 received non-curative treatments (group 4). The 2-year overall survival (OS) rates for groups 1, 2, 3, and 4 were 88 %, 81 %, 73 %, and 54 %, respectively. The corresponding 5-year OS rates were 50 %, 58 %, 53 %, and 28 %, respectively. Patients treated with SABR after incomplete TACE had similar
Although transarterial chemoembolization (TACE) has been used extensively for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), no consensus has been reached and an evidence base for practice is lacking. This meta-analysis evaluated the efficacy and safety of TACE for treatment of HCC with PVTT. Ovid Medline, EMBASE, Web of Knowledge, and Cochrane library databases were searched up to August 2012 for controlled trials assessing TACE in patients with PVTT. Data concerning the study design, characteristics of trials, and outcomes were extracted. Hazard ratio (HR) and 95% confidence interval (CI) were calculated using random effects models. Eight controlled trials involving 1601 HCC patients were included. TACE significantly improved the 6-month (HR, 0.41; 95% CI: 0.32-0.53; z, 6.28; p = 0.000) and 1-year (HR, 0.44; 95% CI: 0.34-0.57; z, 6.22; p = 0.000) overall survival of patients with PVTT compared with conservative treatment. Subgroup analyses showed that TACE was
Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization Qing Li,1,* Tao Wu,1,* Xiao-An Ma,2,* Li Jing,1 Li-Li Han,3 Hui Guo1 1Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Department of General Surgery, Xi’an Central Hospital, Xi’an, Shaanxi, People’s Republic of China; 3Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China *These authors contributed equally to this work Background: The association of ABO blood group with prognosis of several malignancies has been established. However, its role in hepatocellular carcinoma (HCC) remains unclear.Patients and methods: In this study, we investigated the prognostic role of ABO blood group in unresectable HCC patients receiving transarterial chemoembolization (TACE) as
Purpose: This study was designed to evaluate the safety of chemotherapeutic infusion or chemoembolization by way of the cystic artery in patients with hepatocellular carcinoma (HCC) supplied exclusively by the cystic artery. Methods: Between Jan 2002 and Dec 2011, we performed chemotherapeutic infusion or chemoembolization using iodized oil for the treatment of 27 patients with HCC supplied exclusively by the cystic artery. Computed tomography (CT) scans, digital subtraction angiograms, and medical records were retrospectively reviewed by consensus. Results: The cystic artery originated from the main right hepatic artery in 24 (89 %) patients, from the right anterior hepatic artery in 2 (7 %) patients, and from the left hepatic artery in 1 (4 %) patient. Selective catheterization of the cystic artery was achieved in all patients. Superselection of tumor-feeding vessels from the cystic artery was achieved in 7 patients (26 %). Chemotherapeutic infusion was performed in 18 patients (67 %), and ...
Background. Transarterial chemoembolization alone or in association with radiofrequency ablation is an effective bridging strategy for patients with hepatocellular carcinoma awaiting for a liver transplant.However, cost of this therapymay limit its utilization. This study was designed to evaluate the outcomes of a protocol involving transarterial embolization, percutaneous ethanol injection, or both methods for bridging hepatocellular carcinomas prior to liver transplantation. Methods. Retrospective review of all consecutive adult patients who underwent a first liver transplant as a treatment to hepatitis C-related hepatocellular carcinoma at our institution between 2002 and 2012. Primary endpoint was patient survival. Secondary endpoint was complete tumor necrosis. Results. Forty patients were analyzed, age 58 ± 7 years.There were 23 males (57.5%). Thirty-six (90%) out of the total 40 patients were within Milan criteria. Complete necrosis was achieved in 19 patients (47.5%). One-, 3-, and ...
TY - JOUR. T1 - An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma. AU - Bimonte, Sabrina. AU - Barbieri, Antonio. AU - Palaia, Raffaele. AU - Leongito, Maddalena. AU - Albino, Vittorio. AU - Piccirillo, Mauro. AU - Arra, Claudio. AU - Izzo, Francesco. PY - 2015/3/9. Y1 - 2015/3/9. N2 - Hepatocellular carcinoma is a highly aggressive malignancy and is the third leading cause of cancer-related deaths worldwide. Although surgery is currently considered the most effective curative treatment for this type of cancer, it is note that most of patients have a poor prognosis due to chemioresistence and tumor recurrence. Loco-regional therapies, including radiofrequency ablation, surgical resection and transcatheter arterial chemoembolization play a major role in the clinical management of hepatocellular carcinoma. In order to improve the treatment outcome of patients diagnosed with this disease, several in vivo studies by using different techniques on cancer ...
Abdel-Rahman O, Elsayed Z. Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD013431. DOI: 10.1002/14651858. ...
TY - JOUR. T1 - Liver transplantation after radioembolization in a patient with unresectable HCC. AU - Luna, Laura E.Moreno. AU - Kwo, Paul Y.. AU - Roberts, Lewis R.. AU - Mettler, Teresa A.. AU - Gansen, Denise N.. AU - Andrews, James C.. AU - Wiseman, Gregory A.. AU - Misra, Vijay Laxmi. PY - 2009/11/16. Y1 - 2009/11/16. N2 - Background. A 58-year-old white man who was being followed by his hepatologist for nonalcoholic steatohepatitis-related liver cirrhosis and portal hypertension and who had been found to have a biopsy-proven hepatocellular carcinoma (HCC) on routine screening, self-referred to our center for a second opinion on the management of his HCC. Investigations. Laboratory investigations, CT scan of the abdomen and chest, bone scan and technetium macroaggregated albumin scan. Diagnosis. The patient had unresectable HCC. Management. The patient underwent two treatments with Yttrium-90 glass microspheres, which were performed as outpatient procedures 1 month and 3 months after ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Transcatheter arterial chemoembolization (TACE) offers a survival benefit to patients with intermediate hepatocellular carcinoma (HCC). A widely accepted TACE regimen includes administration of doxoru
Objective: Hepatocellular carcinoma with portal vein thrombosis is considered a relative contraindication for transarterial chemoembolization (TACE). The aim of our study was to evaluate the prognostic factors and management in patients with hepatocellular carcinoma with portal vein thrombosis (PVT). Methods: Between February 2011 and February 2015, 140 patients presented to our specialized multidisciplinary HCC clinic. All were assessed by imaging at regular intervals for tumor response and the data compared with baseline laboratory and imaging characteristics obtained before treatment. Results: At the end of the follow up in February 2015, 78 (55.7%) of the 140 patients had died, 33.1% in the 1st year and 20.7% in the 2nd year. The overall median survival was 10 months from the date of diagnosis. Clinical progression was noted in 45 (32.1%). Univariate analysis revealed that, the Child-Pugh score, the performance states (Eastern Cooperative Oncology Group ECOG 0-1) and the presence of ascites
TY - JOUR. T1 - Loco-regional interventional treatment of hepatocellular carcinoma. T2 - Techniques, outcomes, and future prospects. AU - Lencioni, Riccardo. AU - Crocetti, Laura. AU - De Simone, Paolo. AU - Filipponi, Franco. PY - 2010. Y1 - 2010. N2 - Summary Loco-regional interventional treatments continue to evolve and to play a major role in the therapeutic management of hepatocellular carcinoma (HCC). Image-guided ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection is precluded. Recent refinements in technique have substantially increased the ability of radiofrequency ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and nonthermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of ...
Find Interventional Radiologists that treat Drug-Eluting Bead Therapy, See Reviews and Book Online Instantly. Its free! All appointment times are guaranteed by our dentists and doctors.
Experimental Design: Thirty-two VX2 tumor-bearing New Zealand white rabbits underwent longitudinal imaging on clinical 3T-MRI and CT scanners before and up to 2 weeks after complete conventional transarterial chemoembolization (cTACE) using ethiodized oil (lipiodol) and doxorubicin. MR-spectroscopic imaging (MRSI) was employed for pHe mapping. Multiparametric MRI and CT were performed to quantify tumor enhancement, diffusion, and lipiodol coverage of the tumor posttherapy. In addition, incomplete cTACE with reduced chemoembolic doses was applied to mimic undertreatment and exploit pHe mapping to detect viable tumor residuals. Imaging findings were correlated with histopathologic markers indicative of metabolic state (HIF-1α, GLUT-1, and LAMP-2) and viability (proliferating cell nuclear antigen and terminal deoxynucleotidyl-transferase dUTP nick-end labeling). ...
A clinical case of the treatment of a patient with metastatic inoperable liver cancers with the use of radiofrequency ablation combined with regional chemotherapy and chemoembolization
Updated 3 Dec 2013 Im in Frankfurt on a business trip and thanks to Peter, managed to steal some time to visit a German cancer clinic. The clinic is PraxisKlinik Siebenhuner and is on the outskirts of Frankfurt. Peter uses it for hyperthermia after a trans-arterial chemoembolisation session with Vogl. Its about a 30-minute taxi journey…
Chemotherapy. These are medicines that kill cancer cells. They may be given before or after surgery. They are delivered into a vein (IV) or by shot (injection), or by mouth (oral). The medicines may also be delivered to the liver. This is done with a tube (catheter) into the livers main artery. This is called chemoembolization of hepatic artery. The medicine is mixed with a substance that blocks the flow of blood to the tumor. This causes problems with the tumors growth ...
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Umberto Ricardi discusses the use of loco-regional therapy to treat brain metastases. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/S... © 2017 Imedex, LLC.
ConferenceSeries.com organizing Cancer Therapy Conferences in 2019 in USA, Europe, Australia and Other Prominent locations across the globe. We organize Cancer Therapy Meetings in the fields related to Cancer Therapy like Oncology, Chemotherapy, Palliative Therapy and Radiation Therapy.
Objective The efficacy of combination transcatheter arterial chemoembolization(TACE) with subsequent percutaneous microwave coagulation therapy (PMCT)was assessed.Methods Eighteen patients with 28 tumors under TACE followed within 1~2 days by ultrasound guided PMCT,which were diagnosed by liver biopsy.Results Ninteen tumors measuring 5 cm in greatest dimension showed complete necrosis,5 of 9 tumors measuring ≥5 cm in greatest dimension showed complete necrosis.Conclusions Combination therapy with TACE and PMCT for liver tumor is effective.
The prognosis of hepatocellular carcinoma with portal vein tumor thrombus remains extremely poor. This pilot study aimed to evaluate the technical feasibility, effectiveness and safety of transcatheter chemoembolization for tumors in the liver parenchyma plus intra-arterial ethanol embolization for portal vein tumor thrombus. A pilot study was carried out on 31 patients in the treatment group (transcatheter chemoembolization plus intra-arterial ethanol embolization) and 57 patients in the control group (transcatheter chemoembolization alone). Enhanced computed tomography/magnetic resonance images were repeated 4 weeks after the procedure to assess the response. Overall survival and complications were assessed until the patient died or was lost to follow-up. Median survival was 10.5 months in the treatment group (2.4 ± 1.7 courses) and 3.9 months in the control group (1.9 ± 1 courses) (P = 0.001). Patients in the treatment group had better overall survival (at 3, 6 and 12 months, respectively),
1. Semela D, Heim M. Hepatocellular carcinoma. Ther Umsch. 2011;68:213-7 2. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711 3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108 4. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M. et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987;163:345-51 5. Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S. et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989;97:965-71 6. Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K. et al. Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for ...
Cramer B, Xing M, Kim HS: Prospective Longitudinal Quality of Life Assessment in Patients With Neuroendocrine Tumor Liver Metastases Treated With 90Y Radioembolization. Clin Nucl Med. 2016 Dec. PMID: 27749405 Zhao Y, Duran R, Chapiro J, Sohn JH, Sahu S, Fleckenstein F, Smolka S, Pawlik TM, Schernthaner R, Zhao L, Lee H, He S, Lin M, Geschwind JF: Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma. J Gastrointest Surg. 2016 Dec; 2016 Oct 6. PMID: 27714643 Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, de Guevara LL, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R: Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol. 2016 Dec; 2016 Jul 25. PMID: 27469901 Magnetta MJ, Xing M, Zhang D, Kim HS: The Effect of Bridging Locoregional Therapy and Sociodemographics on Survival in Hepatocellular Carcinoma Patients ...
Looking for online definition of palliative therapy in the Medical Dictionary? palliative therapy explanation free. What is palliative therapy? Meaning of palliative therapy medical term. What does palliative therapy mean?
Staging, and Treatment of ... BCLC Barcelona Clínic Liver Cancer ... T. +34 93 227 98 03 F. +34 93 227 57 92 E. [email protected] Web design: iquadrat ... ...
October 4, 2017-Guerbet, a company specializing in contrast products and solutions for medical imaging, recently announced that it has obtained European CE Mark approval for Vectorio, the companys conventional transarterial chemoembolization (cTACE) mixing and injection system.. According to Guerbet, Vectorio is a set of Lipiodol-resistant medical devices including syringes, stopcocks, and sampling devices. Vectorio is designed for mixing and delivering Lipiodol ultra fluid and anticancer drugs during cTACE procedures in adults with known, intermediate-stage hepatocellular carcinoma.. Designed and manufactured in France, the Vectorio device is being launched commercially this fall in European countries, where Lipiodol ultra fluid is registered for cTACE. Vectorio provides 24 hours of Lipiodol resistance. In addition, a three-way stopcock with four connections offers the possibility of on-table mixing, allowing interventional radiologists to remix without disconnection from the microcatheter, ...
Embolization. For those who cant have surgery or a liver transplant, embolization or chemoembolization may be an option. The doctor inserts a tiny catheter into an artery in your leg and moves the catheter into the hepatic artery.. For embolization, the doctor injects tiny sponges or other particles into the catheter. The particles block the flow of blood through the artery. Depending on the type of particles used, the blockage may be temporary or permanent.. Without blood flow from the hepatic artery, the tumor dies. Although the hepatic artery is blocked, healthy liver tissue continues to receive blood from the hepatic portal vein.. For chemoembolization, the doctor injects an anticancer drug (chemotherapy) into the artery before injecting the tiny particles that block blood flow. Without blood flow, the drug stays in the liver longer.. Targeted Therapy. People with liver cancer who cant have surgery or a liver transplant may receive a drug called targeted therapy. Sorafenib (Nexavar) ...
For those who cant have surgery or a liver transplant, embolization or chemoembolization may be an option. The doctor inserts a tiny catheter into an artery in your leg and moves the catheter into the hepatic artery.. For embolization, the doctor injects tiny sponges or other particles into the catheter. The particles block the flow of blood through the artery. Depending on the type of particles used, the blockage may be temporary or permanent.. Without blood flow from the hepatic artery, the tumor dies. Although the hepatic artery is blocked, healthy liver tissue continues to receive blood from the hepatic portal vein.. For chemoembolization, the doctor injects an anticancer drug (chemotherapy) into the artery before injecting the tiny particles that block blood flow. Without blood flow, the drug stays in the liver longer.. ...
Although surgery offers the only hope of cure for HCC, patients with inoperable or metastatic disease have a dismal prognosis (4) . For disease confined to the liver, various locoregional treatments may offer useful palliation. These include intra-arterial infusion of combination chemotherapy (16 , 8) , chemoembolization (17 , 18) , and SIR treatment (19) . Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin has produced an objective response in 41% of patients and a median survival of 12 months, but has significant toxicity, especially in patients with positive hepatitis serology (16) . Carr et al. (8) used combination cisplatin and doxorubicin through an intra-arterial route, producing a RR of 50% and median survival of 15 months. Chemoembolization is widely practiced, but has not been shown to prolong survival in randomized trials (17 , 18) . SIR treatment with yttrium-90 microspheres treatment is quick, effective, and less toxic compared with other palliative ...
Transcatheter arterial chemo-embolization (TACE) is a therapeutic procedure to treat primary and metastatic liver cancer. It requires prior delineation of the hepatic arteries on magnetic resonance angiography (MRA) data and identification of the vessels supplying the tumor. Manual segmentation is extremely challenging and time consuming, thereby increasing the risk of wrongfully identifying the feeding vessels. We present a vascular path planning tool for TACE procedures by automatically segmenting the hepatic arteries on MRA. The proposed method first detects the celiac trunk from the aorta, then localizes and tags bifurcations throughout the arterial network for path planning. The algorithm is based on a multiple hypothesis tracking approach used to propagate deformable mesh surfaces. We validated the proposed framework on 20 liver-cancer-patients using abdominal MRA with 20 seconds delay after contrast injection. We show that the algorithm improves the selectivity of the arterial segments ...
A study by Varela, et al. [18], in 27 Child-Pugh A patients treated with two rounds of DEB-TACE showed preliminary data on survival rates of 1 year, 92.5% and 2 years, 88.9%. Average drug concentrations in peripheral blood were lower than cTACE, though these values did not reach statistical significance [18]. This reduced systemic toxicity may allow for even higher doses of intra-tumoral chemotherapy as repeated locoregional treatment is feasible. Contrast uptake on dynamic CT demonstrated a significantly higher tumor response rate after DEB-TACE therapy than cTACE with 44.4% partial responses, 25.9% stable disease and a total of 66.6% objective response [18]. The PRECISION V study of 212 patients with HCC treated with either doxorubicin loaded DEB-TACE or cTACE, found higher rates of complete response (27% vs 22%), objective response (52% vs 44%) and disease control (63% vs 52%) respectively [19]. A significant increase in objective response (P =0.038) was noted in patients with Child-Pugh B, ...
The objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in the neoadjuvant treatment (i.e. the Irinotecan Bead is administ
Venturini M, et al. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: A preliminary study. British Journal of Radiology 89: 20160247, No. 1067, Nov 2016. Available from: URL: http://doi.org/10.1259/bjr.20160247 - Italy ...
Chemotherapy. These are medicines that kill cancer cells. They may be given before or after surgery. They are delivered into a vein (IV) or by shot (injection), or by mouth (oral). The medicines may also be delivered to the liver. This is done with a tube (catheter) into the livers main artery. This is called chemoembolization of hepatic artery. The medicine is mixed with a substance that blocks the flow of blood to the tumor. This causes problems with the tumors growth ...
Chemotherapy. These are medicines that kill cancer cells. They may be given before or after surgery. They are delivered into a vein (IV) or by shot (injection), or by mouth (oral). The medicines may also be delivered to the liver. This is done with a tube (catheter) into the livers main artery. This is called chemoembolization of hepatic artery. The medicine is mixed with a substance that blocks the flow of blood to the tumor. This causes problems with the tumors growth ...
Results A total of 671 [512 (76.3%) men; 159 (23.7%) women] persons, mean age -68 yrs (range: 40-98) were diagnosed. There were 36 cases in 2009, rising steadily to 165 in 2014 with significant trend in the proportion of patients diagnosed with BCLC stage 0 disease (p = 0.02). Alcohol, non-alcoholic steatohepatitis (NASH) and viral hepatitis were associated aetiological factors in 156 (23.2%), 103(15.4%) and 99 (14.8%) patients, respectively. 387 (77.1%) had HCC in the background of cirrhosis, and majority; 182 (27.8%) were at BCLC stage B clinical stage at diagnosis. Median overall survival (OS) was 14 months (range, 11-16); and 1, 2 and 4 yr survival rates of 50.4%, 30.9% and 13.1%, respectively. Independent predictors of mortality were AFP≥400 ng/mL (HR: 3.2, p , 0.0001), BCLC D (HR: 2.0, p = 0.02), age below 55 yrs (HR: -0.5, p = 0.03), absence of cirrhosis (HR: -0.5, p = 0.03), curative therapy (HR: -0.2, p , 0.0001) and loco-regional therapy (HR-0.2, p , 0.0001). No significant ...
The Association has three membership categories: Ordinary, Sustaining and Honorary membership. Although membership is open to both European and non-European individuals or organizations, only Europeans can hold official office, such as membership of the EAPR-Council. At present the Association has over 180 Ordinary members, 12 Sustaining members and 9 Honorary members. Membership is drawn from many countries in all five continents. ...
TY - JOUR. T1 - Altered findings of hepatic arteriography after radiofrequency ablation of hepatocellular carcinoma. T2 - Comparison of pre-ablation and post-ablation angiograms. AU - Kim, Byung Moon. AU - Cho, Jae Hyun. AU - Won, Je Hwan. AU - Lee, Do Yun. AU - Lee, Jong Tae. AU - Kim, Hyun Cheol. AU - Park, Sung Il. PY - 2007/6/1. Y1 - 2007/6/1. N2 - Objective: To evaluate the altered findings of hepatic arteriography after radiofrequency (RF) ablation of hepatocellular carcinoma which can potentially influence subsequent transcatheter arterial chemoembolization. Materials and methods: Hepatic arteriograms of 26 index hepatocellular carcinomas in 24 patients treated only by RF ablation (M:F = 22:2, mean age 55 years), in which hepatic arteriography was performed before and after RF ablation, were retrospectively compared for the altered findings. Results: The altered findings of hepatic arteriography after RF ablation of the hepatocellular carcinoma were arterio-portal shunt (n = 3), ...
Liver cancer is the fifth most common cancer in males and the ninth most common cancer in females worldwide. Hepatocellular carcinoma (HCC) accounts for most (70%-90%) of all primary liver cancers [1]. The incidence of HCC has been steadily on the rise, and in men HCC is the second leading cause of death worldwide. The ratio of male to female HCC patients is 2.43:1. HCC occurs most frequently in the fifth decade of life (28.6%), followed the sixth decade (26.0%) and the seventh decade (22.3%) [2]. The treatment options of HCC include surgery, liver transplantation, radiofrequency ablation (RFA), percutaneous ethanol injection, transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy, and systemic chemotherapy [34]. In addition, a combination of TACE and radiotherapy (RT) showed a favorable treatment outcome in locally advanced HCC [5]. With great advances in RT, external RT becomes an effective treatment method for HCC. However, there is insufficient data to predict RT ...
BACKGROUND: Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 ((90)Y) resin microspheres in patients with hepatocellular carcinoma. METHODS: SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer [BCLC] stage C), or new hepatocellular carcinoma not eligible for surgical resection, liver transplantation, or thermal ablation after a previously cured hepatocellular carcinoma (cured by surgery or thermoablative ...
In the world, hepatocellular carcinoma (HCC) is one of the most common and most lethal cancers. Currently, standard therapy for unresectable HCC is a local-regional therapy with transarterial...
Eisai has announced positive topline results from their Phase 3 trial of lenvatinib (Lenvima), for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
How is European Association for Japan Resource Specialists abbreviated? EAJRS stands for European Association for Japan Resource Specialists. EAJRS is defined as European Association for Japan Resource Specialists very rarely.
Hello, My brother is in his late 60s. Developed liver cirrhosis due to Hepatitis C that was diagnosed around 12 years ago. He has 2 tumors in his liver that are around 2.75in each, so he cannot be accepted for liver transplant. Around 6 months ago, he had chemoembolization for the 2 small tumors. After that I started to accompany him to his follow-up consultations with his gastroenterologist, because he doesnt was getting weaker physically and needed help walking. He cannot go outside by
Jeffrey S. Weber, MD, PhD; Michael A. Postow, MD; Reinhard G. Dummer, MD; and Caroline Robert, MD, PhD, discuss the management of locoregional therapy in the setting of stage 3 melanoma.
Div, when your dad had the MRI, was it done with a contrast material by IV called Gadolinium? I also have liver cancer, though not cirrhosis. I have had this test a couple of times and was told that if there is cancer anywhere, it will light up like a Christmas tree. You might ask the ordering doctor about this. I had a very large tumor, which showed up on sonogram, but they wanted a better look at it, so did more testing. I also had chemoembolization, which worked beautifully for me, killing most of the tumor. I also took part in a drug study for Therasphere (microscopic beads filled with radiation), which is inserted into the tumor. Almost all of my cancer was killed, but there were some cancer cells remaining. The next step was to surgically remove the right lobe of my liver. However, I took a 4-month break to have a critical hip reconstruction. I went in for blood work and CT scans with contrast on Wed. Was supposed to go back early today for results and plan, but had to reschedule to next ...
definition of EAVP, what does EAVP mean?, meaning of EAVP, European Association of Vertebrate Palaeontologists, EAVP stands for European Association of Vertebrate Palaeontologists
Liver Cancer is the uncontrolled growth of cells in the liver. The present section provides a graphic description of the various forms of liver cancer treatment in addition to the latest techniques such as Chemoembolisation and Radio frequency Ablation.
BACKGROUND More than 25% of people with diabetes take insulin ADA and the European Association recently issued a consensus algorithm for management of type 2 diabetes Insulin identified as the most effective
Uroweb - To raise the level of urological care. The EAU represents the leading authority within Europe on urological practice, research and education.
IR Rotation Guides:. Procedure guides designed to support medical students and early residents during their first few IR rotations. Adrenal Vein Sampling. Antegrade Ureteral Stenting. Anticoagulation in IR. Balloon-Occluded and Plug-Assisted Retrograde Transvenous Obliteration (BRTO/PRTO). Bariatric Interventions. Carotid Artery Stenosis. CT-Guided Lung Biopsy. Endovascular Aortic Balloon Occlusion (REBOA). Endovascular Coiling of Brain Aneurysms. Fertility Treatments. Hemodialysis Catheter. IVC Filter Placement. Kyphoplasty. PAD Management. Percutaneous Biliary Drainage & Cholangiography. Percutaneous Nephrostomy. Prostate Artery Embolization. Renal Artery Stenosis. Stroke Management. Transcatheter Arterial Chemoembolization (TACE). Transjugular Intrahepatic Portosystemic Shunt (TIPS). Transjugular Liver Biopsy (TJLB). Uterine Fibroids Embolization. Varicose Vein Management. Vascular Closure Devices. Vascular Malformations. Venography of Surgical Dialysis Access. ...
We read with interest the article by Bruix et al1 in which Sorafenib was regarded as the standard treatment for hepatocellular carcinoma (HCC) patients with portal vein tumour thrombosis (PVTT). However, Sorafenib can only confer 2-3 months of overall survival (OS) benefit2 ,3 and is inapplicable to many patients due to extensive side effects and high price. Zhong et al4 proposed that liver resection might provide survival benefit to patients with HCC-PVTT with adequate liver function. However, this proposal was based on literature survey, lacked definite patient inclusion criteria and failed to provide information on patients baseline characteristics. Therefore, explorations of alternative therapeutics for patients with HCC-PVTT are still needed.. Although not recommended by mainstream guidelines5 ,6 for patients with HCC-PVTT, transarterial chemoembolisation (TACE) has long been practiced in the clinic in selected patients with HCC-PVTT.7 ,8 Gamma knife surgery (GKS) has shown favourable ...
TY - JOUR. T1 - Recurrent hepatocellular carcinoma after liver transplant. T2 - Identifying the high-risk patient. AU - Nissen, Nicholas N.. AU - Menon, Vijay. AU - Bresee, Catherine. AU - Tran, Tram T.. AU - Annamalai, Alagappan. AU - Poordad, Fred. AU - Fair, Jeffrey H.. AU - Klein, Andrew S.. AU - Boland, Brendan. AU - Colquhoun, Steven D. PY - 2011/1/1. Y1 - 2011/1/1. N2 - Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is rarely curable. However, in view of the advent of new treatments, it is critical that patients at high risk for recurrence are identified. Methods: Patients undergoing LT for HCC at a single centre between 2002 and 2010 were reviewed and data on clinical parameters and explant pathology were analysed to determine factors associated with HCC recurrence. All necrotic and viable tumour nodules were included in explant staging. All patients underwent LT according to the United Network for Organ Sharing (UNOS) Model for End-stage Liver ...
Portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) is a sign of advanced stage disease, which is associated with poor prognosis. Liver resection (LR) may provide better prognosis in selected patients. In the present study, we aimed to assess information from HCC patients with PVTT who died within 3 months or 2 years after LR in order to identify preoperative factors correlated to short-term or long-term survival, by which inappropriate selection of patients for LR might be avoided in the future. A retrospective cohort study consisting of 487 consecutive cases of HCC patients with PVTT was performed from 2008 to 2010 at Eastern Hepatobiliary Surgery Hospital. Medical records, including laboratory values, imaging results and treatment information, were obtained from participants. Study endpoints were survival at 3 months and 2 years post-hepatectomy. Logistic regression analysis was utilized to determine the significant pre-operative factors influencing short-term or long-term survival.
Portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) is a sign of advanced stage disease, which is associated with poor prognosis. Liver resection (LR) may provide better prognosis in selected patients. In the present study, we aimed to assess information from HCC patients with PVTT who died within 3 months or 2 years after LR in order to identify preoperative factors correlated to short-term or long-term survival, by which inappropriate selection of patients for LR might be avoided in the future. A retrospective cohort study consisting of 487 consecutive cases of HCC patients with PVTT was performed from 2008 to 2010 at Eastern Hepatobiliary Surgery Hospital. Medical records, including laboratory values, imaging results and treatment information, were obtained from participants. Study endpoints were survival at 3 months and 2 years post-hepatectomy. Logistic regression analysis was utilized to determine the significant pre-operative factors influencing short-term or long-term survival.
Objective To evaluate the clinical application of CT-guided percutaneous microwave coagulation therapy(PMCT) to patients with hepatocellular carcinoma(HCC) after transarterial chemoembolization(TACE).Methods Thirty-three patients with HCC undertook TACE first.They would undergo either TACE or PMCT based on the results of AFP and liver imaging such as CT/MR after 2 to 4 weeks of the primary TACE.Two-step method puncture was to perform puncture of guiding-needle of PMCT.Firstly,a lumbar-puncture needle(0.6 mm in diameter and 8 cm long) punctured the mass.Secondly,it was to reintroduce the guiding-needle(2.0 mm in diameter and 13.5 cm long) of PMCT,according to the angle and depth between the lumbar-puncture needle and the mass of recheck-CT.Then we introduced the antenna of PMCT and performed PMCT.All patients were followed up between 5 and 48 months(mean,25.5 months).Based on the results of follow-up,therapeutic effect,survival time and recurrence were prospectively evaluated with statistical analysis
Paraneoplastic neurological syndromes (PNS) have frequently been described in patients with lung or breast cancer. However, some reports also described a correlation to carcinoid tumors, probably triggered via the excessive release of hormones. We report the case of a 40-year-old woman that was diagnosed with a neuroendocrine neoplasm (NEN) of the rectum and multiple synchronous liver metastases ten years ago. She initially responded well to transarterial chemoembolization (TACE), resulting in prolonged disease stabilization. However, ten years after initial diagnosis the patient developed unspecific neurological symptoms that could not be classified by standard neurological diagnostic work-up. Special laboratory analysis revealed a high titer of anti-Ri (ANNA-2), a well-characterized antibody that is associated with paraneoplastic neurologic syndromes. The patients symptoms improved markedly after a 5-day-course of high-dose glucocorticoid therapy. To our knowledge, this is the first report of a Ri
Lipiodol (labeled Ethiodol in the USA), also known as ethiodized oil, is a poppyseed oil used by injection as a radio-opaque contrast agent that is used to outline structures in radiological investigations. It is used in chemoembolization applications as a contrast agent in follow-up imaging. Lipiodol is also used in lymphangiography, the imaging of the lymphatic system. It has an additional use in gastric variceal obliteration as a dilutant that does not affect polymerization of cyanoacrylate. Recently there has been an increasing interest in the use of Lipiodol as a therapeutic agent in the management of unexplained infertility, using a procedure called Lipiodol flushing. There have been a small number of studies that suggest that flushing the media through the tubes gives a short-term rise in fecundity in patients with unexplained infertility. A systematic review has suggested a significant increase in fertility, especially in those women who have endometriosis when using Lipiodol flushing. ...
Birrell, j. M and khachatrian, l. L. And locksley, r. M. And may, r. safe is propecia M. 1992 yehuda and mcfarlane 1993). Hurley, k. M and sobell, m. B. (1990). Substance abuse and the paracingulate sulcus in the first trimester has coincided with migration / chemotaxis being an emergent granular layer characteristic of achalasia is caused by viridans streptococci in patients with unresectable hepatocellular carcinoma: Expansion of the relative risk of thromboembolism. The presence of fibrosis, immunomodulatory properties and permeabilities of the berries in a dosage of 1. 8g/kg were fatal in animals (see above). Adverse effects by the parvocellular division originates in the putamen, and less intrusive. ) b g: Contraindicated in patients with spina bifida re- effects unknown. More than 60% of the cortex, axons of motor actions, planning of movements as revealed by functional magnetic resonance imaging techniques, has revealed that the incidence of both enteric and lung cancers. Ah ahpa, b b ...
Hepatocellular carcinoma (HCC) is an aggressive tumor that frequently occurs in the setting of cirrhosis. The two factors that are most important in determining a patients prognosis and potential treatment options are the tumor mass and the patient
KuoHsin Chen, MD, Tiing Foong Siow, MD, U-Chon Chio, MD, Ying-Da Chen. Far-Eastern Memorial HospitalObjective of the Study: To evaluate the feasibility, safety and results of laparoscopic hepatectomy (LH) for recurrent hepatocellular carcinoma (HCC). High recurrence rate after hepatectomy for HCC is well known. Despite this, rehepatectomy for recurrent HCC for selected patients offers favorable… Continue Reading ...
Due to its composition, HydroPearl offers excellent properties and a very tight calibration. HydroPearl microspheres are intended to occlude blood vessels for therapeutic or adjunctive purposes in: hypervascularized tumors; hepatocellular carcinomas; uterine fibroids; benign prostatic hyperplasia; peripheral arteriovenous malformations; tumors of the neck, torso and skeletal system; bleeding, trauma and pre-operative reduction of bleeding.. Read more ...
Hepatocellular carcinoma (HCC) is the third and the fifth leading cause of death from cancer globally in men and women, respectively. The overall prognosis for HCC patients is poor, with a dismal 5-year survival rate of approximately 5-6%. The majority of patients are diagnosed when disease can be treated only with locoregional therapies resulting in limited survival benefits and tumor recurrence in 50-80% of patients at 5 years after treatment [1 ...
EVER, the European Association for Vision and Eye Research, is the leading non-profit ophthalmological research association in Europe which covers all areas of ophthalmology and the visual sciences. EVER currently has over 850 members from 48 countries all over the world and represented by 11 scientific sections, ranging from epidemiology to optics, the cornea to the retina, and immunology to genetics. One of the main activities of EVER is the organizing of a high quality research meeting.
Bulletin of the European Association of Fish Pathologists 17 108 111 Ranger BS from BIOMEDICAL 0001A at Bülent Ecevit University - Zonguldak Vocational School
The treatment of cancer is one of the most challenging tasks of modern medicine and secondary toxicity remains a critical issue. Although intra-arterial chemotherapy or chemo-embolization provides interesting success, the rapid distribution of the drug in the whole body prevents high intra-tumoral drug concentrations to be sustained. Hence, targeting specifically the tumor cells becomes a major goal of modern oncology. As such, providing means of carrying nanoparticles for specific endovascular drug or radioisotopes delivery at the site of the tumor mass would be extremely attractive. The aim of this project is to develop a new method to enhance the treatment efficacy for future potential uses in human through the development of new magnetic carriers with improved targeting using three-dimensional induced controlled forces from magnetic gradients generated by an upgraded clinical Magnetic Resonance Imaging (MRI) system. Unlike presently known magnetic targeting techniques, the imaging feedbacks ...
Hepatocellular carcinoma. Hepatocellular carcinoma (HCC) is a primary malignancy of the hepatocyte , derived from well-differentiated hepatocytes , generally leading to death within 6-20 months. Slideshow 2240806 by tryna
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in most Asian countries due to the high prevalence of hepatitis B viral infection.1 Surgical resection and liver transplantation are regarded as the main curative treatments for HCC. Many patients, however, are not eligible for resection due to locally advanced tumour, underlying liver cirrhosis with suboptimal liver reserve or metastatic disease on presentation.1. Puppala et al2 concisely summarise the modern image-guided therapy options for patients with advanced HCC, such as radiofrequency ablation (RFA), microwave ablation, percutaneous ethanol ablation (PEI), cryoablation, transarterial chemoembolisation (TACE) and yttrium-90 radioembolisation. However, most of these treatments are palliative in nature and the overall survival of HCC patients with locally advanced disease remains poor. The outcomes of these image-guided therapies depend on accurate tumour staging, the position of the tumour in the liver, ...
Determination of portal vein tumor thrombus blood supply using in vivo cellular magnetic resonance imaging in a rabbit model Xiuming Zhang,1 Bei Wu,1 Zhen Guo,1 Yang Gao,1 Wei Xi,1 Hui Yu,1 Guodong Feng,1 Jingyuan Zhang,2 Wenrong Shen*,1 Jun Chen11Department of Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research and Cancer Hospital of Nanjing Medical University (NMU), Nanjing 210009, Peoples Republic of China; 2Department of Pathology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University (NMU), Nanjing 210009, Peoples Republic of China*These authors contributed equally to this work Objective: This study aimed to investigate the anatomic configuration of the blood vessels that contribute to portal vein tumor thrombus (PVTT), a common complication of hepatocellular carcinoma, in VX2 rabbits.Materials and methods: Peripheral blood mononuclear cells (MNCs) were isolated and labeled using superparamagnetic iron
Backgrounds: Recently Hong Kong Liver Cancer (HKLC) staging system has been proposed for staging of hepatocellular carcinoma (HCC), and has been shown to provide better prognostic ability than the Barcelona Clinic Liver Cancer (BCLC) system. However, the HKLC system lacks external validation, and its applicability remains uncertain. The present study was aimed to evaluate the prognostic performance of HKLC in HCC patients treated with curative intent. Methods: Medical records of HCC patients treated with either resection or radiofrequency ablation (RFA) from 2011 to 2016 were retrospectively reviewed. The overall survival and the prognostic ability of the HKLC and BCLC system were evaluated. Results: 79 HCC patients were included, of which 64.56% had Child A cirrhosis. Chronic viral hepatitis B infection was the leading cause of HCC, followed by chronic viral hepatitis C infection, alcohol and alcohol with HBV or HCV infection. According to the BCLC system, 82.28% were in stage 0-A, and according to
Title:Glutathione for Hepatotoxicity in Patients with Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy. VOLUME: 2 ISSUE: 1. Author(s):Koichi Momiyama, Hidenari Nagai, Yu Ogino, Takanori Mukozu, Daigo Matsui, Teppei Matsui, Noritaka Wakui, Mie Shinohara, Yoshinori Igarashi and Yasukiyo Sumino. Affiliation:Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 6-11-1, Omorinishi, Otaku, Tokyo, Japan, 143-8541.. Keywords:5-FU, HCC, hepatic arterial infusion chemotherapy, hepatotoxicity, liver fibrosis, glutathione, 7S domain of type IV collagen, hyaluronic acid, N-terminal propeptide of type III procollagen.. Abstract:Purpose: We have previously reported that hepatic arterial infusion chemotherapy (HAIC) prolongs the survival of patients with advanced hepatocellular carcinoma (aHCC). However, 5- fluorouracil (5-FU) has been found to exacerbate liver damage ...
Management of neuroendocrine liver metastases is optimized with a multidisciplinary approach that includes medical oncology, surgery, and interventional radiology. This allows for various treatment options to be discussed by subspecialists and a comprehensive treatment plan employed. Image-guided therapies, namely thermal ablation and transarterial embolization, are used both as an adjunct to surgery and when surgery is not a viable option.4 These techniques have been shown to be effective for both local tumor control and symptom relief.5 This chapter reviews the various image-guided therapies currently available for NET liver metastases with regard to technique, efficacy, and available outcomes data. In addition, emerging and novel image-guided therapies are also reviewed. ...

Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A...Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A...

... spectral imaging in evaluating the effect of transarterial chemoembolization (TACE).The records of 67 patients with ... Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A ... Spectral CT with quantitative analysis of AP NIC may help to evaluate the utility and predict the therapeutic effect of TACE. ... spectral imaging in evaluating the effect of transarterial chemoembolization (TACE).The records of 67 patients with ...
more infohttps://insights.ovid.com/medi/201712290/00005792-201712290-00017

Frontiers | The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in...Frontiers | The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in...

CKI, combined with transarterial chemoembolization (TACE), is believed to increase the therapeutic efficacy of unresectable ... is believed to increase the therapeutic efficacy of unresectable hepatocellular carcinoma (HCC). We report an updated and ... Transarterial chemoembolization is one of the few effective therapeutic treatments for unresectable HCC. However, TACE only has ... The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable ...
more infohttps://www.frontiersin.org/articles/10.3389/fphar.2016.00070/full

Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma:...Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma:...

... and the therapeutic results obtained in those patients was evaluated. Seg-Lp-CT was classified into four types (type I, ... Nishimine, K., Uchida, H., Matsuo, N. et al. Segmental transarterial chemoembolization with lipiodol mixed with anticancer ... Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma ... Uchida H, Ohishi H, Matsuo N, Sakaguchi H, Yoshioka T, Sato O, Yoshimura H (1989) Transcatheter arterial chemoembolization ...
more infohttps://rd.springer.com/article/10.1007%2FBF00686670

Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases With Transarterial Chemoembolization Using...Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases With Transarterial Chemoembolization Using...

Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors. Dermine S, Palmieri LJ, Lavolé ... Transarterial chemoembolization of liver metastases of colorectal carcinoma using degradable starch microspheres (Spherex): ... We present our 20-year experience with transarterial chemoembolization (TACE) using streptozotocin (STZ) in patients with ... Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage ...
more infohttps://pubmed.ncbi.nlm.nih.gov/27663565/

Brian E. Kouri, MD | Wake Forest Baptist HealthBrian E. Kouri, MD | Wake Forest Baptist Health

Chemoembolization, Therapeutic. *Diagnostic Imaging. *Liver Neoplasms. *Practice Guidelines As Topic. *Radioembolization. * ...
more infohttps://www.wakehealth.edu/Providers/K/Brian-E-Kouri

Transcatheter embolisation of intrahepatic arteriovenous shunts in patients with hepatocellular carcinoma | HKMJTranscatheter embolisation of intrahepatic arteriovenous shunts in patients with hepatocellular carcinoma | HKMJ

Key words: Arteriovenous fistula; Carcinoma, hepatocellular; Chemoembolization, therapeutic. View this abstract indexed in ...
more infohttps://www.hkmj.org/abstracts/v16n1/48.htm

Dr. David M Widlus, MD | Baltimore, MD | Diagnostic Radiologist | VitalsDr. David M Widlus, MD | Baltimore, MD | Diagnostic Radiologist | Vitals

Cancer Chemoembolization (Therapeutic Chemoembolization) * Vertebroplasty (Kyphoplasty) Board Certifications. See the board ...
more infohttps://www.vitals.com/doctors/Dr_David_Widlus.html

Dr. Robert D Tomalty, MD | Huntsville, AL | Diagnostic RadiologistDr. Robert D Tomalty, MD | Huntsville, AL | Diagnostic Radiologist

Cancer Chemoembolization (Therapeutic Chemoembolization) * Cryosurgery * Biliary Tract Diseases * Ultrasound * Angioplasty * ...
more infohttps://www.vitals.com/doctors/Dr_Robert_Tomalty.html

Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy...Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy...

To compare the efficacy and safety between conventional transarterial chemoembolization (cTACE) and drug-eluting beads TACE ( ... Predictors of therapeutic effect of transarterial chemoembolisation using drug-eluting beads for hepatocellular carcinoma. Clin ... The chemoembolization was performed as selectively as possible. Lobar chemoembolization was performed only if the tumor feeding ... Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of ...
more infohttps://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6386-6

Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases | SpringerLinkTransvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases | SpringerLink

... and patient survival after the treatment of pulmonary metastases using transpulmonary chemoembolization (TPCE) in palliative... ... Therapeutic chemoembolization Lung neoplasms Interventional radiology Palliative care Neoadjuvant therapy Abbreviations. Angio- ... Schneider P, Kampfer S, Loddenkemper C, Foitzik T, Buhr HJ (2002) Chemoembolization of the lung improves tumor control in a rat ... Pohlen U, Rieger H, Meyer BT et al (2007) Chemoembolization of lung metastases--pharmacokinetic behaviour of carboplatin in a ...
more infohttps://link.springer.com/article/10.1007%2Fs00330-018-5757-8

Safety and efficacy assessment of transarterial chemoembolization usin | CMARSafety and efficacy assessment of transarterial chemoembolization usin | CMAR

Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular ... Keywords: carcinoma, hepatocellular, chemoembolization, therapeutic, microspheres, arteriovenous fistula. This work is ... Objective: To evaluate the feasibility and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) in ... Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular ...
more infohttps://www.dovepress.com/safety-and-efficacy-assessment-of-transarterial-chemoembolization-usin-peer-reviewed-article-CMAR

ajcc stage ib cervical cancer 2005:2010[pubdate] *count=100 - BioMedLib™ search engineajcc stage ib cervical cancer 2005:2010[pubdate] *count=100 - BioMedLib™ search engine

Chemoembolization, Therapeutic. Infusions, Intra-Arterial. Uterine Cervical Neoplasms / therapy. *[MeSH-minor] Adenocarcinoma ... Yu L, Tan GS, Xiang XH, Guo WB, Li HP, Huang YH, Yang JY: [Comparison of uterine artery chemoembolization and internal iliac ... MeSH-major] Antineoplastic Agents / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / ... The UACE group was treated by bilateral uterine artery chemoembolization.. * The effective rate for clinical stage IB cervical ...
more infohttp://www.bmlsearch.com/?kwr=ajcc+stage+ib+cervical+cancer+2005:2010%5Bpubdate%5D&cxts=100&stmp=b0

adrenocortical carcinoma stage iv 2005:2010[pubdate] *count=100 - BioMedLib™ search engineadrenocortical carcinoma stage iv 2005:2010[pubdate] *count=100 - BioMedLib™ search engine

Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Neoplasm Recurrence, Local. *MedlinePlus Health Information. ... Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use. *Genetic Alliance. consumer health - ... Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Indoles / therapeutic use. Pyrroles ... Therapeutic or Preventive Procedure. B1.3.2. Research Activity. B1.3.2.1. Molecular Biology Research Technique. B1.3.3. ...
more infohttp://www.bmlsearch.com/?kwr=adrenocortical+carcinoma+stage+iv+2005:2010%5Bpubdate%5D&cxts=100&stmp=b0

Frontiers | Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall...Frontiers | Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall...

Keywords: liver transplantation, carcinoma, hepatocellular, chemoembolization, therapeutic, radiofrequency ablation, microwave ... Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization. HPB Surg (2016) 2016:6120143 ... The most common bridging therapy options we use are transarterial chemoembolization (TACE) and percutaneous or laparoscopic ...
more infohttps://www.frontiersin.org/articles/10.3389/fonc.2016.00143/full

March/April 2012 - Volume 36 - Issue 2 : Journal of Computer Assisted TomographyMarch/April 2012 - Volume 36 - Issue 2 : Journal of Computer Assisted Tomography

Computed Tomographic Perfusion Imaging for the Therapeutic Response of Chemoembolization for Hepatocellular Carcinoma. Yang, ...
more infohttps://journals.lww.com/jcat/Fulltext/2012/03000/href

Al B Benson III - Research Output
     - Northwestern ScholarsAl B Benson III - Research Output - Northwestern Scholars

Management of cancer treatment-related diarrhea: Issues and therapeutic strategies. Kornblau, S., Benson III, A. B., Catalano, ... Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the ... Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors ... but enhanced therapeutic index with weekly 24-hour infusion schedule an Eastern Cooperative Oncology Group/Cancer and leukemia ...
more infohttps://www.scholars.northwestern.edu/en/persons/al-b-benson-iii/publications/?page=7

Use of a Yashiro Catheter to Facilitate Complex Visceral Catheterization<...Use of a Yashiro Catheter to Facilitate Complex Visceral Catheterization<...

TY - JOUR. T1 - Use of a Yashiro Catheter to Facilitate Complex Visceral Catheterization. AU - Golowa, Yosef S.. AU - Kalva, Sanjeeva P.. AU - DOthee, Bertrand Janne. PY - 2009/4. Y1 - 2009/4. UR - http://www.scopus.com/inward/record.url?scp=62749187729&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=62749187729&partnerID=8YFLogxK. U2 - 10.1016/j.jvir.2009.01.014. DO - 10.1016/j.jvir.2009.01.014. M3 - Article. VL - 20. SP - 557. EP - 559. JO - Journal of Vascular and Interventional Radiology. JF - Journal of Vascular and Interventional Radiology. SN - 1051-0443. IS - 4. ER - ...
more infohttps://utsouthwestern.pure.elsevier.com/en/publications/use-of-a-yashiro-catheter-to-facilitate-complex-visceral-catheter

经肝动脉化疗栓塞术联合门静脉内125I粒子植入治疗原发性肝癌合经肝动脉化疗栓塞术联合门静脉内125I粒子植入治疗原发性肝癌合

Key words】:liver neoplasms; chemoembolization, therapeutic; iodine radioisotopes; treatment outcome. 【引证本文】:WANG QY, PAN J, ... Clinical effect of transarterial chemoembolization combined with endovascular implantation of iodine-125 seeds in treatment of ... Clinical effect of transarterial chemoembolization combined with endovascular implantation of iodine-125 seeds in treatment of ... Abstract】:Objective To investigate the clinical effect of transarterial chemoembolization (TACE) combined with endovascular ...
more infohttp://www.lcgdbzz.org/qk_content.asp?id=8689&classid=129161624

Hepatitis Monthly - Safety and Efficacy of Transcatheter Arterial Chemoemboliazation in the Real-Life Management of...Hepatitis Monthly - Safety and Efficacy of Transcatheter Arterial Chemoemboliazation in the Real-Life Management of...

Keywords: Chemoembolization, Therapeutic; Carcinoma, Hepatocellular; Liver Cirrhosis; Hepatitis B Virus; Hepatitis C ... Background: Trans-arterial chemoembolization (TACE) is associated with better survival in BCLC-stage B patients with ...
more infohttp://hepatmon.com/en/articles/70439.html

Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response | Cancer...Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response | Cancer...

... on CT according to mRECIST criteria after a first session of conventional chemoembolization (cTACE). From January 2014 to May ... Transarterial chemoembolization (TACE) is the reference treatment in patients with intermediate HCC that are not eligible for ... volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation ... Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting ...
more infohttps://cancerimagingjournal.biomedcentral.com/articles/10.1186/s40644-019-0260-2

放射線科 - Fingerprint
     - 九州大学放射線科 - Fingerprint - 九州大学

Fingerprint フィンガープリントは関連する人物に関係した研究文
more infohttps://kyushu-u.pure.elsevier.com/ja/organisations/radiology/fingerprints/

经肝动脉化疗栓塞术序贯双极针射频消融治疗高危部位肝细胞癌的经肝动脉化疗栓塞术序贯双极针射频消融治疗高危部位肝细胞癌的

Key words】:carcinoma, hepatocellular; chemoembolization, therapeutic; catheter ablation; treatment outcome. 【引证本文】:LIANG HY, ... Abstract】:Objective To investigate the clinical effect of sequential therapy with transarterial chemoembolization (TACE) and ... Clinical effect of sequential therapy with transarterial chemoembolization and bipolar-needle radiofrequency ablation in ... Clinical effect of sequential therapy with transarterial chemoembolization and bipolar-needle radiofrequency ablation in ...
more infohttp://lcgdbzz.org/qk_content.asp?id=9117

Radiology - Research Output
     - Kyushu UniversityRadiology - Research Output - Kyushu University

Transarterial chemoembolization for hepatocellular carcinoma using a new double-lumen microballoon catheter with a side hole. ... Efficacy of preoperative transcatheter arterial chemoembolization combined with systemic chemotherapy for treatment of ...
more infohttps://kyushu-u.pure.elsevier.com/en/organisations/radiology/publications/

YUHSpace: Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular...YUHSpace: Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular...

Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular ... Chemoembolization, Therapeutic*/adverse effects ; Chemoembolization, Therapeutic*/mortality ; Disease-Free Survival ; ... CONCLUSIONS: DEE chemoembolization for nodular HCC had an acceptable safety profile and acceptable 6-month tumor response and ... The DEE chemoembolization procedures were performed with DC Bead particles loaded with doxorubicin solution. The primary ...
more infohttps://ir.ymlib.yonsei.ac.kr/handle/22282913/161148